http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102479497-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2022 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 |
| filingDate | 2018-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102479497-B1 |
| titleOfInvention | Sustained release pharmaceutical formulation of varenicline and preparation method thereof |
| abstract | The present invention provides an oral sustained-release preparation characterized in that it is a sustained-release matrix system comprising varenicline or a pharmaceutically acceptable salt thereof and a matrix polymer. The present invention can provide a sustained-release formulation with improved medication compliance and reduced side effects with once-a-day administration. |
| priorityDate | 2016-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 69.